Q-omics provides the consensus-scored SLC2A4 profile across patient tissues and cancer cell-line models. SLC2A4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SLC2A4 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, SLC2A4 RNA expression shows 15,813 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight READ, BLCA, and UCEC as cancer lineages where SLC2A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A4 survival associations across molecular data types. SLC2A4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A4 RNA expression–survival associations across cancer types. High SLC2A4 expression shows unfavorable associations in READ and UCEC, but favorable associations in LGG, LAML, MESO and KIRC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for SLC2A4 RNA expression.
This table summarizes SLC2A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC2A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A4 shows lower tumor expression in BLCA, HNSC, THCA, BRCA and UCEC and higher tumor expression in KICH. The BLCA box plot shows higher SLC2A4 RNA expression in normal versus tumor tissue (log2 FC = −5.777, t-test p < 0.001).
This table shows molecular features associated with SLC2A4 in patient tissues and cancer cell lines. In patient samples, SLC2A4 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC2A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
